Mazindol ER is under clinical development by NLS Pharmaceutics and currently in Phase II for Narcolepsy. According to GlobalData, Phase II drugs for Narcolepsy have a 59% phase transition success rate ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily ...

For Avadel’s Lumryz, the one-dose extended-release oral suspension that allows narcolepsy patients to sleep through the night, the worst-case scenario is it won't be on the market until 2025 ...

GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of ...

“People who experience SRED are at an increased risk of fatigue, depression and weight gain,” Johnston said. They’re also at ...

Sleep paralysis is a phenomenon that occurs when a person temporarily experiences an inability to move or speak while waking ...

Nightmares and pleasant experiences are part of the dream repertoire of animals, whose sleep patterns resemble those of ...

According to the Centers for Disease Control and Prevention, roughly one in three adults in the U.S. don’t get enough rest or ...

Principal Financial Group Inc. lessened its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free ...

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report)’s share price dropped 3.2% on Tuesday . The stock traded as low ...

Spiromacrocyclic compounds acting as orexin OX2 receptor agonists have been described in an H. Lundbeck A/S patent and reported to be useful for the treatment of type 1 and type 2 narcolepsy.